MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Progressive Supranuclear Palsy: Review On Diagnostic Aspects Based On A Case

    A. Kurniadi (Kabupaten Bekasi, Indonesia)

    Objective: This article was written to enrich the spectrum of PSP case reports, emphasizing the diagnosis aspect. Background: Progressive supranuclear palsy (PSP) is the main…
  • 2023 International Congress

    Selenium mitigates ferroptosis-mediated dopaminergic cell death by regulating the Nrf2/GPX4 pathway: Implication for Parkinson’s disease

    YJ. Jung, H. Choi, E. Oh (Daejeon, Republic of Korea)

    Objective: The objective of this study is to explore the protective properties of selenium in an in vitro PD model, especially focusing on its underlying…
  • 2023 International Congress

    Persistence, Health Care Resource Utilization, and Costs Among OnabotulinumtoxinA-Treated Patients with Cervical Dystonia in the US

    K. Dashtipour, D. Charles, M. Sadeghi, M. Heath, A. Rava, J. Liu, H. Sun, Y. Dong, J. Lee (Loma Linda, USA)

    Objective: To compare health care resource utilization (HCRU) and costs among patients with cervical dystonia (CD) in the US who are persistent vs nonpersistent with…
  • 2023 International Congress

    Using wearable wireless technology to understand the natural history of adrenomyeloneuropathy in both clinic and home settings: 1-year follow-up in the CYGNET study

    C. Bergner, W. Koehler, J. Bonkowsky, C. Stephen, F. Eichler, L. Glenn, M. Engelen (Leipzig, Germany)

    Objective: To assess the feasibility of using wearable wireless motion sensors to quantify disease progression in men with adrenomyeloneuropathy (AMN) enrolled in the CYGNET natural…
  • 2023 International Congress

    Inhibitory and facilitatory alterations in prodromal and de novo Parkinson’s disease

    A. Rizzardi, A. Benussi, A. Pilotto, C. Tirloni, V. Cantoni, C. Zatti, A. Galli, B. Borroni, A. Padovani (Brescia, Italy)

    Objective: The aim of this study was to detect alterations within GABAergic, glutamatergic and cholinergic circuitries in Parkinson’s Disease (PD) patients, including de Novo PD…
  • 2023 International Congress

    Botulinum toxin injections for lingual protrusion dystonia: a review of the muscle target and dosage

    A. Duarte, H. Ghizoni Teive (Curitiba, Brazil)

    Objective: The aim of our study was to perform a literature review about the botulinum toxin types, their dosage and muscle target in the treatment…
  • 2023 International Congress

    Marked reduction of energy supply due to levodopa treatment in patients with Parkinson’s disease and healthy controls

    J. Prasuhn, T. Schiefen, T. Grüber, J. Hekel, J. Uter, J. Steinhardt, B. Wilms, N. Brüggemann (Lübeck, Germany)

    Objective: To investigate the influence of a standardized, placebo-controlled administration of levodopa on cerebral bioenergetics in patients with Parkinson’s disease (PwPD) and healthy controls (HCs).…
  • 2023 International Congress

    Supine hypertension is longitudinally associated with cognitive decline in Parkinson disease independent of orthostatic hypotension

    C. Miller-Patterson, J. Hsu, M. Barrett, L. Cloud, T. Chelimsky (Richmond, USA)

    Objective: To determine whether orthostatic hypotension (OH) and/or supine hypertension (SH) are longitudinally associated with cognitive decline in Parkinson disease (PD). Background: Cognitive impairment is…
  • 2023 International Congress

    Multiple methods to improve recruitment, enrollment, and retention of study participants for validation of the Fragile X-Associated Tremor Ataxia Syndrome Rating Scale (FXTAS-RS)

    M. Tosin, D. Hessl, J. O'Keefe, D. Hall (Chicago, USA)

    Objective: Describe multiple methods used to recruit, enroll and retain participants to validate the FXTAS-RS. Background: A clinical outcome assessment (COA) must be developed to…
  • 2023 International Congress

    Hypoxia‑induced astrocyte activation and its protective effect on Parkinson’s disease

    M. Kim, S-H. Kim, HN. Choi, JY. Je, SP. Yun (Jinju, Republic of Korea)

    Objective: In this study, we aimed to investigate whether hypoxic conditions can activate cerebral astrocytes and explore their protective effects on α-synuclein pre-formed fibril (PFF)-treated…
  • « Previous Page
  • 1
  • …
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • 186
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley